Clinical applications of genome editing to HIV cure

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 539-544

  Wang, Cathy X ^a   Cannon, Paula M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical trials; Genome editing; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; ZINC FINGER NUCLEASE; GUIDE RNA;

ARTICLE; CD4+ T LYMPHOCYTE; GAIN OF FUNCTION MUTATION; GENE DISRUPTION; GENE THERAPY; GENOME; GENOME EDITING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; SAFETY; VIRUS GENOME; VIRUS LOAD; CONTROLLED CLINICAL TRIAL (TOPIC); GENE EDITING; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; RNA EDITING; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CONTROLLED CLINICAL TRIALS AS TOPIC; GENE EDITING; GENETIC THERAPY; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, CCR5; RNA EDITING; RNA, GUIDE;

EID: 85002749257     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0233     Document Type: Article

References (72)

1. Peterson CW, Younan P, Jerome KR, Kiem HP. Combinatorial anti-HIV gene therapy: Using a multipronged approach to reach beyond HAART. Gene Ther 2013;20:695-702.
2. Morgan RA, Walker R, Carter CS, et al. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 2005;16:1065-1074.
3. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005;12:900-909.
4. Podsakoff GM, Engel BC, Carbonaro DA, et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005;12:77-86.
5. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006;103:17372-17377.
6. van Lunzen J, Glaunsinger T, Stahmer I, et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007;15:1024-1033.
7. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009;15:285-292.
8. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010;2:36ra43.
9. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006;13:1031-1049.
10. Trobridge GD. Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 2011;11: 581-593.
11. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: Prospects and challenges. Nat Med 2015;21:121-131.
12. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther 2016;24:430-446.
13. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 2012;12:51-58.
14. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
15. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011;117:2791-2799.
16. Hoffmann C. The epidemiology of HIV coreceptor tropism. Eur J Med Res 2007;12:385-390.
17. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3¢A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-795.
18. Hutter G, Schneider T, Thiel E. Transplantation of selected or transgenic blood stem cells - A future treatment for HIV/AIDS? J Int AIDS Soc 2009;12:10.
19. Henrich TJ. HIV eradication: Is cord blood the answer? Lancet HIV 2015;2:e219-e220.
20. Hutter G. More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med 2014;371:2437-2438.
21. Tey SK, Bollard CM, Heslop HE. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol 2006; 84:281-289.
22. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008;26:808-816.
23. Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger). 2015;2009. Available at: https://clinicaltrials.gov/ ct2/show/NCT00842634 (Last accessed October 10, 2016).
24. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.
25. Kutzler MA, Jacobson JM. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr Opin HIV AIDS 2008;3:131-135.
26. Phase 1 Dose Escalation Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nu-cleases in HIV-Infected Patients. 2010. Available at: https:// clinicaltrials.gov/ct2/show/NCT01044654 (Last accessed October 10, 2016).
27. Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects. 2010. Available at: https://clinicaltrials.gov/ct2/ show/NCT01252641 (Last accessed October 10, 2016).
28. Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T. 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT01543152 (Last accessed October 10, 2016).
29. Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT02225665 (Last accessed October 10, 2016).
30. A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients. 2015. Available at: https://clinicaltrials. gov/ct2/show/NCT02388594 (Last accessed October 10, 2016).
31. Wang CX, Cannon PM. The clinical applications of genome editing in HIV. Blood 2016;127:2546-2552.
32. Maintained Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks. Vol. 2015. Madrid: ESGCT; 2013. Available at: www.natap.org/2013/HIV/103013-01.htm (Last accessed October 10, 2016).
33. Virologic Response During ART Interruption After CCR5-Cell Modification with SB-728-T. Vol. 2015. Washington, DC: 54th ICAAC; 2014. Available at: www.natap.org/2014/ ICAAC/ICAAC-36.htm (Last accessed October 10, 2016).
34. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/ progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28: 839-847.
35. Li L, Krymskaya L, Wang J, et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 2013;21:1259-1269.
36. Cannon PM, Henley J, Wood T, et al. Electroporation of ZFN mRNA enables efficient CCR5 gene disruption in mobilized blood hematopoietic stem cells at clinical scale. Mol Ther 2013;21:S71.
37. Wang J, Exline CM, DeClercq JJ, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol 2015;33:1256-1263.
38. Holt N, Exline CM, Mulhern O, et al. Zinc finger nuclease editing of hematopoietic stem cells as an anti-HIV therapy. In: Humanized Mice for HIV Research. Poluektova LY, Garcia-Martinez JV, Koyanagi Y, Manz MG, Tager AM, eds. New York: Springer, 2014, pp. 407-416.
39. Safety Study of Zinc Finger Nuclease CCR5-Modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients. 2015. Available at: https://clinicaltrials.gov/ct2/ show/NCT02500849 (Last accessed October 10, 2016).
40. Oh DY, Jessen H, Kucherer C, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One 2008;3:e2747.
41. Kordelas L, Verheyen J, Beelen DW, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 2014;371:880-882.
42. Henrich TJ, Hanhauser E, Hu Z, et al. Viremic control and viral coreceptor usage in two HIV-1-infected persons ho-mozygous for CCR5 Delta32. AIDS 2015;29:867-876.
43. Liu S, Kong C, Wu J, Ying H, Zhu H. Effect of CCR5-Delta32 heterozygosity on HIV-1 susceptibility: A meta-analysis. PLoS One 2012;7:e35020.
44. Voit RA, McMahon MA, Sawyer SL, Porteus MH. Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. Mol Ther 2013;21:786-795.
45. Sather BD, Romano Ibarra GS, Sommer K, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 2015;7:307ra156.
46. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2012;2:a006940.
47. Xu H, Svarovskaia ES, Barr R, et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 2004; 101:5652-5657.
48. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009;5:e1000443.
49. McNatt MW, Zang T, Hatziioannou T, et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009;5:e1000300.
50. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005;15:73-78.
51. Jung U, Urak K, Veillette M, et al. Preclinical assessment of mutant human TRIM5alpha as an anti-HIV-1 transgene. Hum Gene Ther 2015;26:664-679.
52. Santa-Marta M, de Brito PM, Godinho-Santos A, Gon-calves J. Host factors and HIV-1 replication: Clinical evidence and potential therapeutic approaches. Front Immunol 2013;4:343.
53. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-947.
54. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009;5:e1000791.
55. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;330:1551-1557.
56. Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 2015;33:985-989.
57. Wang J, DeClercq JJ, Hayward SB, et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res 2016;44:e30.
58. Peterson CW, Wang J, Norman KK, et al. Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. Blood 2016;127:2416-2426.
59. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510:235-240.
60. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 2003;112:1561-1570.
61. Davis BM, Humeau L, Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther 2004;9:160-172.
62. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007;316:1912-1915.
63. Karpinski J, Chemnitz J, Hauber I, et al. Universal Tre (uTre) recombinase specifically targets the majority of HIV-1 isolates. J Int AIDS Soc 2014;17(Suppl 3):19706.
64. Qu X, Wang P, Ding D, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013;41:7771-7782.
65. Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510.
66. Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A 2014;111:11461-11466.
67. Zhu W, Lei R, Le Duff Y, et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 2015;12:22.
68. Ebina H, Kanemura Y, Misawa N, et al. A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One 2015;10:e0120047.
69. Aubert M, Ryu BY, Banks L, Rawlings DJ, Scharenberg AM, Jerome KR. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One 2011;6:e16825.
70. Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 2016;24:522-526.
71. Wang Z, Pan Q, Gendron P, et al. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep 2016;15:481-489.
72. Kaminski R, Bella R, Yin C, et al. Excision of HIV-1 DNA by gene editing: A proof-of-concept in vivo study. Gene Ther 2016;23:690-695.